Compare PTCT & TERN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | PTCT | TERN |
|---|---|---|
| Founded | 1998 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.7B | 4.8B |
| IPO Year | 2006 | 2021 |
| Metric | PTCT | TERN |
|---|---|---|
| Price | $72.08 | $52.97 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 17 | 12 |
| Target Price | ★ $80.65 | $45.22 |
| AVG Volume (30 Days) | 1.4M | ★ 3.5M |
| Earning Date | 05-07-2026 | 05-14-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 264.48 | 8.04 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $264,734,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.70 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 36.19 | N/A |
| 52 Week Low | $43.18 | $2.82 |
| 52 Week High | $87.50 | $53.19 |
| Indicator | PTCT | TERN |
|---|---|---|
| Relative Strength Index (RSI) | 53.41 | 74.51 |
| Support Level | $61.59 | $52.42 |
| Resistance Level | $79.67 | $53.19 |
| Average True Range (ATR) | 3.55 | 0.07 |
| MACD | 0.59 | -0.31 |
| Stochastic Oscillator | 49.85 | 97.30 |
PTC Therapeutics Inc is a biopharmaceutical company that discovers, develops and commercializes clinically differentiated medicines that provide benefits to children and adults living with rare disorders. Its diversified therapeutic portfolio that includes several commercial products and product candidates in various stages of development, including discovery, research and clinical stages, focused on the development of new treatments for multiple therapeutic areas for rare diseases relating to neurology and metabolism. The company views its operations and manages its business in one operating segment: life science, which is focused on the discovery, development and commercialization of the company's clinically differentiated medicines that provide benefits to patients with rare disorders.
Terns Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. The company is developing a portfolio of small-molecule single-agent and combination therapy candidates for the treatment of non-alcoholic steatohepatitis, NASH, and other chronic liver diseases. Its product candidates include TERN-701, TERN-601, TERN-501 and TERN-800.